Oncology Clinic, CSK MON WIM, Warsaw, Poland.
J Cancer Res Clin Oncol. 2010 Mar;136(3):371-8. doi: 10.1007/s00432-009-0664-7. Epub 2009 Aug 27.
This single-centre retrospective analysis of data from three randomised studies and two expanded-access studies compared the effect of interferon (IFN)-alfa, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).
The analysis included 292 patients: 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alfa 9 MU t.i.w.
Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alfa at extending mean time to progression of pre-existing bone lesions (P = 0.057). Compared with sorafenib, sunitinib significantly decreased formation (P = 0.034) and prolonged time to occurrence of new bone lesions (P = 0.047).
Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.
本单中心回顾性分析了来自三项随机研究和两项扩展准入研究的数据，比较了干扰素（IFN）-α、舒尼替尼和索拉非尼对肾细胞癌（RCC）患者转移性骨病变发生和进展的影响。
该分析纳入了 292 名患者：107 名患者接受舒尼替尼 50mg/天的 6 周周期治疗（方案 4/2），147 名患者接受索拉非尼 800mg/天治疗，38 名患者接受安慰剂或 IFN-α 9MU 每周三次治疗。
82 名患者报告存在转移性骨病变，其中 30 名患者发生进展。210 名患者中有 23 名出现新的骨病变。总体而言，舒尼替尼在延长预先存在的骨病变进展的平均时间方面似乎比索拉非尼或 IFN-α更有效（P=0.057）。与索拉非尼相比，舒尼替尼显著减少了新骨病变的形成（P=0.034）并延长了其发生时间（P=0.047）。
需要进一步评估这些治疗方法对 RCC 骨转移的影响。
